Company Encyclopedia
View More
name
Novavax
NVAX.US
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine.
1.946 T
NVAX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking104/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-100.06%E
    • Profit Margin32.10%A
    • Gross Margin-47.21%E
  • Growth ScoreB
    • Revenue YoY20.27%B
    • Net Profit YoY219.97%A
    • Total Assets YoY-31.10%E
    • Net Assets YoY70.24%A
  • Cash ScoreB
    • Cash Flow Margin311.53%C
    • OCF YoY20.27%B
  • Operating ScoreB
    • Turnover0.74B
  • Debt ScoreE
    • Gearing Ratio113.28%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors

    Novavax Inc.'s stock fell 1.35% to $6.60 on Tuesday, underperforming compared to competitors like Johnson & Johnson, which rose slightly. The NASDAQ and Dow Jones indices both saw gains. Novavax's stock is 42.86% below its 52-week high. Trading volume was 2.5 million, below the 50-day average of 4.2 million.

    Dow Jones·
    US
    NVAX
    +0.29%
    Dow Jones·
    US
    NVAX
    +0.29%

    Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval

    Moderna and other pharmaceutical stocks fell after reports that the US FDA plans to tighten vaccine approval processes. This follows claims by FDA's chief medical officer, Vinay Prasad, that COVID-19 vaccines were linked to child deaths. Moderna shares dropped 7%, Novavax 5.1%, BioNTech 5.6%, and Pfizer 1.8%.

    fidelity·
    US
    MRNA
    +1.23%
    fidelity·
    US
    MRNA
    +1.23%

    U.S. vaccine stocks fell in pre-market trading, with Moderna down over 3%, BioNTech and Novavax down over 1%

    Wallstreetcn·
    US
    NVAX
    +0.29%
    US
    MRNA
    +1.23%
    US
    BNTX
    -0.75%
    Wallstreetcn·
    US
    NVAX
    +0.29%
    US
    MRNA
    +1.23%
    US
    BNTX
    -0.75%

    Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

    Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results, highlighting a strategic shift from COVID-19 sales to a focus on research and development, particularly in collaboration with Sanofi. The company is recognized as one of the most oversold biotech stocks to invest in.

    MSN·
    US
    NVAX
    +0.29%
    MSN·
    US
    NVAX
    +0.29%

    Novavax Inc. Stock Rises Monday, Still Underperforms Market

    Novavax Inc. shares rose 2.47% to $6.63 on Monday, marking the second consecutive day of gains. Despite this increase, the stock remains 42.60% below its 52-week high of $11.55. The NASDAQ Composite Index rose 2.69%, and the Dow Jones Industrial Average increased by 0.44%. Novavax's trading volume was below its 50-day average. Competitors like Johnson & Johnson, Pfizer, and Merck also saw stock increases.

    Dow Jones·
    US
    NVAX
    +0.29%
    Dow Jones·
    US
    NVAX
    +0.29%
    © 2025 Longbridge｜Disclaimer